Today’s Short Interest Alert: After Reaching Milestone, Is Stemline Therapeutics Incorporated (NASDAQ:STML)’s Short Interest Revealing Something?

November 16, 2016 - By Marie Mckinney   ·   0 Comments

Today's Short Interest Alert: After Reaching Milestone, Is Stemline Therapeutics Incorporated (NASDAQ:STML)’s Short Interest Revealing Something?

The stock of Stemline Therapeutics Incorporated (NASDAQ:STML) registered a decrease of 4.02% in short interest. STML’s total short interest was 586,700 shares in November as published by FINRA. Its down 4.02% from 611,300 shares, reported previously. With 145,800 shares average volume, it will take short sellers 4 days to cover their STML’s short positions. The short interest to Stemline Therapeutics Incorporated’s float is 3.76%. About 161,309 shares traded hands. Stemline Therapeutics Inc (NASDAQ:STML) has risen 108.04% since April 14, 2016 and is uptrending. It has outperformed by 103.36% the S&P500.

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering, acquiring, developing and commercializing oncology therapeutics. The company has a market cap of $217.14 million. The Firm is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. It currently has negative earnings. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), present on a range of hematologic cancers.

Insitutional Activity: The institutional sentiment increased to 1.08 in Q2 2016. Its up 0.12, from 0.96 in 2016Q1. The ratio increased, as 9 funds sold all Stemline Therapeutics Inc shares owned while 15 reduced positions. 8 funds bought stakes while 18 increased positions. They now own 9.63 million shares or 1.71% less from 9.80 million shares in 2016Q1.
Schwab Charles Investment Mgmt Inc has 26,000 shares for 0% of their US portfolio. Oxford Asset Mgmt has 0.03% invested in the company for 90,956 shares. Amer Grp holds 9,705 shares or 0% of its portfolio. Citigroup holds 237 shares or 0% of its portfolio. Wells Fargo Co Mn has invested 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML). Baker Bros Lp reported 333,497 shares or 0.02% of all its holdings. Moreover, Nationwide Fund Advsr has 0% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 22,395 shares. The Delaware-based Blackrock Advisors has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). California Employees Retirement Systems accumulated 31,100 shares or 0% of the stock. The New York-based Blackrock has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). Ladenburg Thalmann owns 1,394 shares or 0% of their US portfolio. Teachers accumulated 0% or 22,853 shares. Stoneridge Investment Ptnrs Limited Liability Com last reported 0.03% of its portfolio in the stock. Millennium Mngmt Ltd Liability holds 0% or 97,683 shares in its portfolio. Moreover, Timessquare Mgmt Ltd Com has 0.04% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 950,005 shares.

STML Company Profile

Stemline Therapeutics, Inc., incorporated on August 8, 2003, is a clinical-stage biopharmaceutical firm focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Firm is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Another recent and important Stemline Therapeutics Inc (NASDAQ:STML) news was published by Marketwatch.com which published an article titled: “Virtual Stock Exchange” on August 22, 2012.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marie Mckinney


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>